APOE and Alzheimer disease: Estradiol-17beta-benzoate was also identified as an upstream regulator, corroborating findings that estrogen signaling is an important component of sex-dependent differences in AD pathophysiology and may be an important treatment target in APOE4 carriers (Saleh et al., 2023).